A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Principal Investigator

Angela Ricci

Study Number

AALL1732

Summary

This is a risk-adapted research study for children aged (1yr -25yrs) with newly diagnosed high risk B-Lymphoblastic Leukemia (HR B-ALL), Mixed Phenotype Acute Leukemia (MPAL), or disseminated B-Lymphoblastic Lymphoma (B-LLy). This study wants to see if adding the experimental drug Inotuzumab ozogamicin blinatumomab to standard chemotherapy maintains or improves outcomes in patients with the above types of cancers. All participants will receive the same therapy for the first two phases of the study, Induction and Consolidation. Thereafter, participants will receive therapy adapted for their type of cancer.

Phase

III

Contact

Jennifer Kayleigh Whitcomb Coombs

Available at the following location(s)

• Lebanon

View more details at ClinicalTrials.gov

Do you need help with some of the labels on this page?
Read our glossary of terms